Why LeonaBio, Inc.’s (LONA) Stock Is Down 14.64%

By Jenna Brashear
November 17, 2026
Featured Tickers:

Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate LeonaBio, Inc. before investing.

In this article, we go over a few key elements for understanding LeonaBio, Inc.’s stock price such as:

  • LeonaBio, Inc.’s current stock price and volume
  • Why LeonaBio, Inc.’s stock price changed recently
  • Upgrades and downgrades for LONA from analysts
  • LONA’s stock price momentum as measured by its relative strength

About LeonaBio, Inc. (LONA)

Before we jump into LeonaBio, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

LeonaBio, Inc., clinical-stage biopharmaceutical company, engages in the development of novel therapeutics for high unmet medical needs, including treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis. The company’s lead products include lasofoxifene and ATH-1105, a novel small molecule therapies with the potential to address devastating diseases where current treatment options are limited or ineffective. Its product pipeline includes ATH-1105 for the treatment of amyotrophic lateral sclerosis, which is in phase 1 clinical trial; ATH-1020 for the treatment of diabetic neuropathy, which is in phase 1 clinical trial; and ATH-1017 for the treatment of Alzheimer’s disease and Parkinson’s disease, which is in phase 2 clinical trial, as well as early compounds which is in preclinical phase. The company was formerly known as Athira Pharma, Inc. and changed its name to LeonaBio, Inc. in January 2026. LeonaBio, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.

Want to learn more about LeonaBio, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about LeonaBio, Inc..

Learn More About A+ Investor

LeonaBio, Inc.’s Stock Price as of Market Close

As of November 17, 2026, 9:30 AM, CST, LeonaBio, Inc.’s stock price was $3.170.

LeonaBio, Inc. is down 1.86% from its previous closing price of $3.230.

During the last market session, LeonaBio, Inc.’s stock traded between $3.170 and $3.170. Currently, there are approximately 23.73 million shares outstanding for LeonaBio, Inc..

LeonaBio, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

LeonaBio, Inc. Stock Price History

LeonaBio, Inc.’s (LONA) price is currently down 35.83% so far this month.

During the month of November, LeonaBio, Inc.’s stock price has reached a high of $5.030 and a low of $3.170.

Over the last year, LeonaBio, Inc. has hit prices as high as $14.210 and as low as $2.210.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused LeonaBio, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of November 16, 2026, there were analysts who downgraded LeonaBio, Inc.’s stock and analysts who upgraded over the last month.

Additionally, you'll want to evaluate LeonaBio, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on LeonaBio, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

LeonaBio, Inc.’s current valuation based on AAII’s Value Grade is a B, which means it is considered to be Value.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about LeonaBio, Inc. (LONA) by visiting AAII Stock Evaluator.

Relative Price Strength of LeonaBio, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of November 16, 2026, LeonaBio, Inc. has a weighted four-quarter relative price strength of -7.76%, which translates to a Momentum Score of 32 and is considered to be Weak.

Want to learn more about how LeonaBio, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

LeonaBio, Inc. Stock Price: Bottom Line

As of November 17, 2026, LeonaBio, Inc.’s stock price is $3.170, which is down 1.86% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like LeonaBio, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.

Learn More About A+ Investor

Find New Stock Opportunities With Included With AAII Platinum
High Relative Dividend
Yield Screen:
8.7% Compared to S&P 500
at only 6.9%

Since Inception. Data as of 12/31/2024.




Try AAII Platinum and get full access to
769.3% Stock Superstars Portfolio Total Return Since Inception
Compare to:
710.3% iShare DOW Jones
U.S. Index ETF (IYY)

SSR Group 3 O'Shaughnessy portfolio has a 411.2% gain since inception performance compared to IYY at only 119.1%% Performance as of 11/29/24.

Get your free copy of our special report analyzing the tech stocks most likely to outperform the market.

Download the FREE Report Here:

BECOME A MEMBER FOR ONLY $2

Get access to powerful investment discovery tools and a wealth of investment education to help you achieve your financial goals.